North American Biologicals, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Announces a public offering of 4.2 mil. shares of common stock. The Miami, Florida-based provider of human blood plasma elements and plasma/sera-based diagnostic products will offer 2.7 mil. shares, and two selling shareholders will offer 1.5 mil. Assuming the company's planned selling price of $6.50 per share, NABI will gain net proceeds of approximately $15.5 mil. through its 2.7 mil. shares. Additional proceeds could be realized through the sale of 630,000 over-allotment shares by underwriters Raymond James-& Associates and NatWest Securities Limited.
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.